Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.
The increasing number and density of the human population, the emergence of lethal influenza strains, and the potential use of designer influenza virus as a bioweapon, collectively highlight a critical need for more rapid production of influenza vaccines and less invasive means of delivery. We have developed a nonreplicative adenovirus-vectored influenza vaccine that can be produced without the prerequisite of growing influenza virus. This new class of vaccines can be administered as a nasal spray or skin patch by personnel without medical training. We report here that adenovirus-vectored nasal and epicutaneous influenza vaccines were well tolerated by human volunteers. The nasal vaccine was more potent than its epicutaneous counterpart under the adjuvant-free experimental condition. These results provide the foundation for further human testing of needleless vectored vaccines as promising alternatives to current vaccines.
Van Kampen
Kent R
KR
Vaxin Inc., VH-501, 1670 University Blvd., Birmingham, AL 35294, USA.
Shi
Zhongkai
Z
Gao
Peng
P
Zhang
Jianfeng
J
Foster
K Wade
KW
Chen
Dung-Tsa
DT
Marks
Donald
D
Elmets
Craig A
CA
Tang
De-chu C
DC
D000256:Adenoviridae / Q000235:genetics* / Q000276:immunology*; D000279:Administration, Cutaneous; D000281:Administration, Intranasal; D000328:Adult; D002460:Cell Line; D004890:Erythema / Q000139:chemically induced; D005822:Genetic Vectors; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D008297:Male
D007252:Influenza Vaccines